Antigen associated with Type I diabetes mellitus

ABSTRACT

A 69 kD protein, designated PM-1, is expressed in human pancreatic islet cells and a human insulinoma. The amino acid sequence of the protein has been determined. Autoantibodies to the PM-1 protein have been found in sera of prediabetic patients. Natural, synthetic or recombinant forms of the PM-1 protein can be used in immunochemical assays to detect anti-PM-1-autoantibodies and to identify patients at risk of developing diabetes.

GOVERNMENT SUPPORT

The work leading to this invention was supported, in part, by researchgrants from the United States government.

RELATED APPLICATIONS

"This application is a divisional application of Ser. No. 08/307,485filed on Sep. 16, 1994, pending, which in turn is a continuationapplication of Ser. No. 07/901,523 filed on Jun. 19, 1992, abandoned,which is a continuation-in-part application of Ser. No. 07/788,118 filedon Nov. 1, 1991 now abandoned. The contents of all of the aforementionedapplication(s) are hereby incorporated by reference."

BACKGROUND OF THE INVENTION

There is evidence that insulin-dependent diabetes mellitus (IDDM) is achronic autoimmune disease in which the presence of autoantibodies suchas cytoplasmic islet cell antibodies (ICA), anti-glutamic aciddecarboxylase (GAD) autoantibodies and anti-insulin autoantibodies arefound years before the clinical onset of the disease (Eisenbarth, G.S.(1986) N. Engl. J. Med. 314:1360-1368). A common feature of Type Idiabetes and other autoimmune diseases is a humoral immune response thatcan be manifested by the appearance of autoantibodies against cellularproteins (Tan, E.M. (1991) Cell 67:841-842). To date, only a fewautoantigens associated with Type I diabetes mellitus have beenidentified, namely insulin (Palmer, J.P. et al. (1983) Science222:1337-1339), GAD (Baekkeskov, S. et al. (1990) Nature 347:151-156)and carboxypeptidase H (Castano, L. et al. (1991) J. Clin. Endocr.Metab, 73:1197-1201), and the glycolipids GT3 (Gillard, B.K., et al.(1989) Journal Immunol. Methods 142:3826-3832) and GM2-1 (Dotta, F., etal. (1992) Endocrinology 130:37-42).

Recently cDNA encoding a fragment of carboxypeptidase H, agranule-associated enzyme, has been reported to react with sera fromprediabetic patients (Gillard, B.K., et al., supra) and another proteinexpressed in a μgtll phage from a human islet library appear to berecognized by IDDM sera (Rabin, D. U., et al. (1992) Diabetes41:183-186). Cellular proteins of unknown sequence whose molecularweights are 38 kD (Roep, B.O., at al. (1991) Lancet 337:1439-1441), 52kD (Karounos, D. G., and J. W. Thomas (1990) Diabetes 89:1085-1090), and69 kD (Martin, J. M., at al. (1991) Ann, Med. 23:447-452), have alsobeen reported to be recognized by a humoral and/or a cellular immuneresponse. It is of interest that almost all patients with Type Idiabetes have elevated levels of IgG anti-bovine serum albumin (BSA)antibodies which precipitate a M_(r) 69,000 islet peptide which mayrepresent a target antigen for cow milk induced islet autoimmunity(Martin, J. M., et al., supra; and Dosh, H-M, et al. (1991) Pediatr.Adolesc. Endocrinol. 21:). The identification of additional antigensassociated with the development of diabetes could improve the ability ofclinicians to evaluate the risk of development of the disease.

SUMMARY OF THE INVENTION

This invention pertains to a neuroendocrine protein antigen which isassociated with Type I diabetes mellitus, to nucleic acid encoding theprotein and to methods and reagents for detecting antibody against theprotein and identifying individuals at risk of developing Type Idiabetes mellitus. The protein, designated PM-1, is a 69 kD antigen(determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis(SDS-PAGE)) expressed by human pancreatic islet cells. The nucleotidesequence of cDNA encoding the PM-1 protein and the deduced amino acidsequence of the protein have been determined and are shown in theSequence Listing. PM-1 protein can be produced by isolating the proteinfrom cells which express the protein, such as islet cells, or cellsderived therefrom, or by synthesizing the protein chemically or byrecombinant DNA techniques.

Autoantibodies to the PM-1 protein have been found in serum of someprediabetic individuals (who later developed overt diabetes) but havenot been found in serum of non-diabetic individuals. Thus, anti-PM-1autoantibodies are associated with development of diabetes.Immunoreactive forms of the PM-1 protein can be used in immunochemicalassays to detect the presence of such autoantibodies in biological fluidto thereby identify individuals at risk of developing diabetes. The PM-1protein, or an antigenic fragment thereof, are useful in methods totreat or prevent the development of Type I diabetes. Therapeuticcompositions containing the PM-1 protein or an antigenic fragment can beadministered to a diabetic individual or a prediabetic individual atrisk of developing diabetes, to tolerize the individual or block theimmune response of the individual to the PM-1 protein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the reactivity of sera from a prediabetic patient withpurified PM-1 clone. The clone did not react with a control sera.

FIG. 2 is the nucleotide sequence and deduced amino acid sequence of thePM-1 protein. Underlined are: (a) the first upstream in frame stop codon(TAA) at nucleotide -72; and (b) polyadenylation signal 23 bp upstreamof the poly(A) tail. Homologous subunits with bovine serum albumin (BSA)are in boxes. The potential N-linked glycosylation site is indicated byasterisk. Potential phosphorylation sites are as follows: PKC (proteinkinase C); CK2 (casein kinase II) and AMP (cAMP/cGMP-dependent kinase).The amidation site is indicated as AMD.

FIG. 3 is a schematic representation of the strategy used to sequencecDNA encoding the PM-1 protein. The direction of sequencing usingsynthetic oligonucleotide primers is indicated by arrows. Restrictionsites are A:Acc II, B:Bgl II, H:Hgi AI, M:Mae II, and N:Nde I. FIG. 4shows regions of similarity between the PM-1 protein and BSA. FIG. 5 isa Kyte & Doolittle hydrophobicity plot generated using the deduced aminoacid sequence of the PM-1 protein.

FIG. 6 shows the results of Northern blot analysis of total mRNA from acell line and various tissues with a PM-1 cDNA probe. The probehybridized with a 2 Kb mRNA in total RNA from rat pancreas, brain,cerebellum (in the latter two tissues with an additional 5 Kb band).Hybridization with a 2 Kb total RNA band was also detected with a rodentislet cell (RIN 1046-38).

FIG. 7 shows the results of Northern blot analysis of total RNA fromvarious cell lines with a PM-1 cDNA probe. The probe hybridized with RNAfrom a human islet carcinoid cell line (BON-1) and three rodent isletcell lines (RIN 1046-38, beta TC-1 and alpha TC-6) but not with RNA fromnon-islet cell lines (HepG2-hepatoma, HeLa-fibroblast,JEG-choriocarcinoma).

FIG. 8 shows the results of Western Blot analysis of three cell linehomogenates. The post-immune antibody generated against the C-terminusof the PM-1 protein appears to recognize a band at 69 kD in RIN 1046-38.

DETAILED DESCRIPTION OF THE INVENTION

The PM-1 protein, is a neuroendocrine protein having a molecular weightof about 69 kD (determined by SDS-PAGE). The PM-1 protein is expressedby human pancreatic β-islet cells and a human insulinoma. The amino acidsequence of the PM-1 protein and the nucleotide sequence of cDNAencoding the protein are given in the Sequence Listing below.

The PM-1 cDNA comprises a 1785 bp nucleotide sequence which includes a5' 178-noncoding sequence of a 1449-bp open reading frame and a 3' 155bp-noncoding sequence. The open reading frame of the cDNA that can betranslated from two mRNA species of 2 Kb and 5 Kb respectively, predictsa 483 amino acid protein, with a potential N-linked glycoslation site. Acanonical polyadenylation signal AATAAA is present 23 bp up-stream ofthe poly(A) tail. The native PM-1 molecule migrates to 69 kD in aSDS-PAGE as detected with specific antibodies generated to an internaland a C-terminus polypeptide.

The PM-1 protein can be obtained in native form by isolation from cellswhich express the antigen such as cell lines derived from β-islet cells.Alternatively, the protein may be synthesized chemically by, forexample, the solid phase process of Merrifield.

The PM-1 protein can also be produced as a recombinant protein. Nucleicacid (DNA or RNA) encoding the PM-1 protein is inserted into anexpression vector, such as a plasmid or viral nucleic acid, inconjunction with appropriate genetic regulatory elements. Nucleic acidencoding PM-1 protein can be produced de novo by, for example, the cDNAcloning procedures described below or it can be obtained from availableclones. Alternatively, DNA encoding PM-1 protein can be synthesizedchemically according to the nucleotide sequence (or a functionalequivalent thereof) given in the Sequence Listing. The recombinantvector is then introduced into a vector compatible host cell. The hostcell is cultured in a suitable medium, under conditions which allowexpression and, if appropriate, secretion of the protein. Isolation ofthe recombinant PM-1 protein from the cells or cell culture medium canbe accomplished by standard procedures, including ion-exchangechromatography, gel filtration chromatography, ultrafiltration,electrophoresis or immunopurification with antibodies specific for theprotein. PM-1 protein is isolated such that the protein is substantiallyfree of cellular material or culture medium when produced by recombinantDNA techniques, or substantially free of chemical precursors or otherchemicals when synthesized chemically.

Antigenic fragments or peptides derived from the PM-1 protein are withinthe scope of the invention. Fragments within the scope of the inventioninclude those which induce an immune response in mammals, preferablyhumans, such as the production of IgG and IgM antibodies or elicit aT-cell response such as T-cell proliferation and/or lymphokine secretionand/or the induction of T-cell anergy. Fragments of the nucleic acidsequence coding for the PM-1 protein are also within the scope of theinvention. As used herein, a fragment of a nucleic acid sequence codingfor the PM-1 protein refers to a nucleotide sequence having fewer basesthan the nucleotide sequence coding for the entire amino acid sequenceof the PM-1 protein. Nucleic acid sequences used in any embodiment ofthis invention can be cDNA as described herein, or alternatively, can beany oligodeoxynucleotide sequence having all or a portion of a sequencerepresented herein, or their functional equivalents. Sucholigodeoxynucleotide sequences can be produced chemically ormechanically using known techniques. A functional equivalent of anoligonucleotide sequence is one which is capable of hybridizing to acomplementary oligonucleotide to which the sequence shown in theSequence Listing or fragment thereof hybridizes or a sequencecomplementary to the sequence shown in the Sequence Listing.

Given the nucleic acid sequence and deduced amino acid sequence of thePM-1 protein, it is possible to identify peptides which contain T- orB-cell epitopes. An epitope is the basic element or smallest unit ofrecognition by a receptor where the epitope comprises amino acidresidues essential to receptor recognition. For example, peptidescontaining T cell epitopes associated with interaction with the T-cellreceptor (TCR) on helper T-cells can be identified. These T cellepitopes are usually at least 7 amino acid residues in length and, whenassociated with the MHC II glycoprotein present on the surface ofantigen-presenting cells, form a complex that interacts with the TCR.Relevant peptides comprising at least one T cell epitope of the PM-1protein can be identified by dividing the PM-1 protein into overlappingor non-overlapping peptides of desired lengths, which may be producedrecombinantly or synthetically. The peptides can be cultured in thepresence of antigen-presenting cells in a standard T-cell proliferationassay-to determine the ability of the peptide to stimulate T-cellproliferation as indicated by, for example, cellular uptake of labeledthymidine. Peptides derived from the PM-1 protein with alteredstructures can be designed which retain their ability to complex withMHC II glycoprotein but fail to effect reaction with TCR by assessingthe ability of these altered peptides to inhibit the T-cellproliferation in the presence of known activators in this assay.

It is possible to modify the structure of the PM-1 protein or peptidethereof for such purposes as increasing solubility, enhancingtherapeutic or preventive efficacy, or stability (e.g., shelf life exvivo, and resistance to proteolytic degradation in vivo). A modifiedPM-1 protein or modified peptide can be produced in which the amino acidsequence has been altered, such as by amino acid substitution, deletion,or addition, to modify immunogenicity and/or increase therapeuticeffectiveness or to which a component has been added for the samepurpose. For example, additional amino acid residues derived from thePM-1 sequence or other sequence can be attached to either the aminoterminus, the carboxy terminus, or both the amino terminus and carboxyterminus of the PM-1 protein. Non-PM-1 derived sequences includeresidues which may increase solubility or facilitate purification, suchas a sequence attached to the PM-1 protein to aid purification ofprotein produced by recombinant technique. Site-directed mutagenesis ofDNA encoding the PM-1 protein or a peptide thereof can be used to modifythe structure of the PM-1 protein or peptide. Such methods may involvePCR (Ho et al., Gene, 77:51-59 (1989)) or total synthesis of mutatedgenes (Hostomsky, Z., e al., Biochem. Biophvs. Res. Comm., 161:1056-1063(1989)).

The PM-1 protein can be employed in novel therapeutic methods to treatan autoimmune disease in an individual. The PM-1 protein, or antigenicfragment thereof, can be administered to a diabetic or prediabeticindividual to prevent the progression or development of Type I diabetesin the individual. The PM-1 protein, or at least one antigenic fragment,in the form of a therapeutic composition, is administered simultaneouslyor sequentially to the individual in an amount effective to prevent theprogression or development of diabetes in the individual. In addition,the therapeutic composition can be administered under non-immunogenicconditions to tolerize the individual to the PM-1 protein, rather thanelicit an immune response. As used herein, tolerization is defined asnon-responsiveness or diminution in symptoms upon exposure to the PM-1protein. Techniques for administration of tolerizing doses of antigensare known in the art, including administration of the PM-1 protein, orfragment thereof, in the absence of adjuvant and/or in soluble form.Administration of a peptide derived from the PM-1 protein comprising atleast one T cell epitope may tolerize appropriate T cell subpopulationssuch that they become unresponsive to the PM-1 protein. Therapeuticmethods that utilize antagonist peptides of the PM-1 protein which bindthe MHC II glycoprotein but result in a complex which is not interactivewith the TCR can also be used.

The PM-1 protein or peptide thereof may be administered alone or inconcert with anti-CD4 antibodies or other CD4 blockers. This approach toconferring tolerance is disclosed in U.S. Pat. Nos. 4,681,760 and4,904,481. In this approach, the antigen and the anti-CD4 antibodies orimmunoreactive fragments are administered concomitantly. By"concomitant" administration is meant within a time frame which permitsthe anti-CD4 component to block the helper T-cell response to theantigen. The nature of "concomitant" in this sense is described in theabove-referenced U.S. patents, incorporated herein by reference.

The PM-1 protein or fragment thereof is combined with a pharmaceuticallyacceptable carrier or diluent to form a therapeutic composition.Pharmaceutically acceptable carriers include polyethylene glycol (Wie etal. International Archives of Allergy and Applied Immunology 64:84-99(1981)) and liposomes (Strejan et al. Journal of Neuroimmunology 7:27(1984)). Pharmaceutically acceptable diluents include saline and aqueousbuffer solutions. Such compositions will generally be administered byinjection subcutaneously, intravenously or intraperitoneally, oraladministration, (e.g., as in the form of a capsule) inhalation,transdermal application or rectal administration.

Sequence analysis of the PM-1 protein revealed two regions of similaritywith bovine serum albumin (BSA) (FIG. 4). These regions of similaritymay contain epitopes shared by the PM-1 molecule and BSA. It has beenshown that many patients with Type I diabetes have elevated levels ofanti-IgG anti-BSA antibodies. Thus, BSA may represent a target antigenfor cow milk induced islet autoimmunity (Martin, J. M., et al., supra).Peptides comprising amino acid residues shared by the PM-1 protein andBSA may be useful in the form of a therapeutic composition to treat anautoimmune disease, such as Type I diabetes in an individual. Atherapeutic composition comprising a pharmaceutically acceptable carrieror diluent and one or both of the following peptides can beadministered: Phe-Asp-Lys-Leu-Lys-Xaa₁ -Xaa₂ -Val; and Xaa₃ -Xaa₄-Gly-Ala-Cys-Leu-Xaa₅ -Pro, where Xaa₁ is Met or His, Xaa₂ is Asp orLeu, Xaa₃ is Glu or Asp, Xaa₄ is Glu or Lys, and Xaa₅ is Glu or Leu.Such compositions are administered to the individual in an amounteffective to treat the autoimmune disease. Additional amino acidresidues derived from the PM-1 protein or BSA can be attached to eitherthe amino terminus, carboxy terminus or both the amino terminus andcarboxy terminus of these peptides.

Antibodies reactive with the PM-1 protein can be produced by standardtechniques. An animal such as amouse or rabbit is immunized with animmunogenic form of the PM-1 protein (e.g., all or a portion of the PM-1protein which is capable of eliciting an antibody response). Techniquesfor conferring immunogenicity on a protein or peptide subunit includeconjugation to carriers or other techniques well known in the art. ThePM-1 protein or immunogenic peptide can be administered in the presenceof adjuvant. The progress of immunization can be monitored by detectionof antibody titers in plasma or serum standard ELISA or otherimmunoassay can be used with the immunogen as antigen to assess thelevels of antibodies.

Following immunization, anti-PM-1 antisera is obtained and, if desired,polyclonal anti-PM-1 antibodies isolated from the serum. To producemonoclonal antibodies, antibody producing cells (lymphocytes) areharvested from an immunized animal and fused by standard somatic cellfusion procedures with immortalizing cells such as myeloma cells toyield hybridoma cells. Hybridoma cells can be screened immunochemicallyfor production of antibodies reactive with the PM-1 protein.

Autoantibodies to the PM-1 protein have been found in serum of some ICApositive prediabetic individuals (who later developed overt diabetes).These autoantibodies have not been found in the serum of non-diabeticindividuals. Anti-PM-1 autoantibodies are associated with development ofdiabetes and the detection of these antibodies in an individual providesan indication of the individual's risk of developing diabetes.

The PM-1 protein can be used in immunochemical assays to detect thepresence of autoantibodies against the antigen in a biological fluid andidentify an individual at risk of developing diabetes. The PM-1 proteinis contacted with the biological fluid to be tested under conditionswhich allow the antigen to complex with antibody in the fluid. Thedetection of complexes formed between the PM-1 protein or peptide andantibody is indicative of the presence of antibody against PM-1 proteinin the fluid.

A preferred assay type is a solid phase immunometric assay. In assays ofthis type, purified PM-1 protein is immobilized on a solid phasesupport. The support is incubated with the sample of biological fluid tobe tested. The incubation is performed under conditions which allowcomplexation between immobilized PM-1 protein and antibody against theprotein. The solid phase support is then separated from the sample and alabeled anti-(human IgG) antibody is used to detect human anti-PM-1antibody bound to the support. The amount of label associated with thesupport is compared to positive and negative controls to assess thepresence or absence of anti-PM-1 antibody.

In these assays, an immunoreactive form of the PM-1 protein or peptidethereof are used. Native, synthetic or recombinant purified forms of thewhole molecule, or portions immunoreactive with an antibody against PM-1may be used. In addition, modified PM-1 protein which has an amino acidsequence sufficiently duplicative of the PM-1 amino acid sequence (givenin the Sequence Listing) so that they are immunoreactive with anautoantibody against PM-1 and provide an assay of suitable sensitivityand reliability can be used.

In the solid phase immunometric assay, purified PM-1 antigen can beadsorbed or chemically coupled to a solid phase support. Various solidphase supports can be used, such as beads formed of glass, polystyrene,polypropylene, dextran or other material. Other suitable solid phasesupports include tubes or plates formed from or coated with thesematerials.

The PM-1 protein can be either covalently or non-covalently bound to thesolid phase support by techniques such as covalent bonding via an amideor ester linkage or adsorption. After the PM-1 protein is affixed to thesolid phase, the solid phase support can be post-coated with an animalprotein to reduce non-specific adsorption of protein to the supportsurface.

The support containing PM-1 protein functions to selectivelyinsolubilize antibody in the liquid sample tested. In a blood test foranti-PM-1 antibody, the support is incubated with blood plasma or serum.Before incubation, plasma or serum can be diluted with normal animalplasma or serum. The diluent plasma or serum is derived from the sameanimal species that is the source of the anti-(human IgG) antibody. Thepreferred anti-(human IgG) antibody is goat anti-(human IgG) antibody.Thus, in the preferred format, the diluent would be goat serum orplasma.

The conditions of incubation, e.g., pH and temperature, and the durationof incubation are not crucial. These parameters can be optimized byroutine experimentation. Generally, the incubation will be run for 1-2hours at about 45° C. in a buffer of pH 7-8.

After incubation, the solid phase support and the sample are separatedby any conventional technique such as sedimentation or centrifugation.The solid phase support then may be washed free of sample to eliminateany interfering substances.

To assess human antibody bound to the solid phase support, a labeledanti-(human IgG) antibody (tracer) is used. Generally, the solid phasesupport is incubated with a solution of the labeled anti-(human IgG)antibody which contains a small amount (about 1%) of the serum or plasmaof the animal species which serves as the source of the anti-(human IgG)antibody. Anti-(human IgG) antibody can be obtained from any animalsource. However, goat anti-(human IgG) antibody is preferred. Theanti-(human IgG) antibody can be an antibody against the Fc fragment ofhuman IgG, for example, goat anti-(human IgG) F_(c) antibody.

The anti-(human IgG) antibody can be labeled with a radioactive materialsuch as ¹²⁵ Iodine, with an optical label, such as a fluorescentmaterial, or with an enzyme such as horseradish peroxidase. Theantihuman antibody can also be biotinylated and labeled avidin used todetect its binding to the solid phase support.

After incubation with the labeled antibody, the solid phase support isseparated from the solution and the amount of label associated with thesupport is evaluated. The label may be detected by a gamma counter ifthe label is a radioactive gamma emitter, or by a fluorimeter, if thelabel is a fluorescent material. In the case of an enzyme, the label maybe detected colorimetrically employing a substrate for the enzyme.

The amount of label associated with the support is compared withpositive and negative controls in order to determine the presence ofanti-PM-1 antibody. The controls are generally run concomitantly withthe sample to be tested. A positive control is a serum containingantibody against the PM-1 protein; a negative control is a serum fromindividuals (e.g., non-prediabetic individuals) which does not containantibody against the PM-1 protein.

For convenience and standardization, reagents for the performance of thesolid phase assay can be assembled in assay kits. A kit for screeningblood, for example, can include the following components in separatecontainers:

(a) a solid phase support coated with PM-1 protein;

(b) optionally, a diluent for the serum or plasma sample, e.g., normalgoat serum or plasma;

(c) a labeled anti-(human IgG) antibody, e.g., goat anti-(human IgG)antibody in buffered, aqueous solution containing about 1% goat serum orplasma;

(d) optionally, a positive control, i.e., serum containing antibodyagainst PM-1 protein; and

(e) optionally, but preferred, a negative control, e.g., serum whichdoes not contain antibody against PM-1 protein. If the label is anenzyme, an additional component of the kit can be the substrate for theenzyme.

Other assay formats can be used to test for antibody against the PM-1protein. One type is an antigen sandwich assay. In this assay, a labeledPM-1 protein is used in place of anti-(human IgG) antibody to detectanti-PM-1 antibody bound to the solid phase support. The assay is basedin principle on the bivalency of antibody molecules. One binding site ofthe antibody binds the antigen affixed to the solid phase support; thesecond is available for binding the labeled antigen. The assay procedureis essentially the same as described for the immunometric assay exceptthat after incubation with the sample, the support is incubated with asolution of labeled PM-1 protein. The PM-1 protein can be labeled withradioisotope, an enzyme, etc. for this type of assay.

The following examples describe the isolation of cDNA clones from ahuman islet λgtll expression library using sera of prediabetic patients.The putative polypeptide encoded by the longest open reading frame ofPM-1 clones has a molecular weight of 54,600. On Western blotsimmunoreactive PM-1 has a molecular weight of 69 kD suggestingglycosylation or aberrant migration on SDS-PAGE.

EXAMPLE 1 Isolation of Clones Encoding PM-1 cDNA From λgtll ExpressionLibraries

Two libraries, a human islet library and a human insulinoma library wereused to identify and isolate clones encoding PM-1 cDNA. A λgtll cDNAlibrary was constructed from human islet poly(A+) RNA by Clontech (PaloAlto, CA). Approximately 1×10⁶ plaques were obtained with 80% beingrecombinants. Human Insulinoma poly(A+) RNA was isolated and then cDNAproduced and packaged into the λgtll phage (Huynh, J. V., et al. (1985)In: Glover DM (ed) DNA Cloning Techniques. IRL Press, Oxford pp. 49-78).

Sera obtained from first degree relatives of patients with Type Idiabetes which patients had progressed to overt disease and whoexpressed high titers of Islet Cell Antibodies (>80 Juvenile DiabetesFoundation Units) were used to screen the libraries. The sera wererepeatedly absorbed with a protein lysate of a wild type λgtll-infectedEscherichia coli (Y1090) (Sambrook, J., et al. (1989) Molecular Cloning:A Laboratory Manual, 12-25-12.28, Cold Spring Harbor Laboratory Press,Cold Spring Harbor, NY) in order to remove anti-E. coli antibodies. Theabsorbed sera, either controls or relatives sera, that continued to givean unacceptably high level of reactivity to host cells were notutilized. The absorbed antibodies were stored at +20° C. in the presenceof 0.05% sodium azide until used for immunological screening.Originally, a pool of three sera were used to identify a positive cloneand subsequently sera of three other relatives were studied. Ten normalindividuals sera were also tested for reactivity with the positiveclone.

The phage human islet λgtll expression library was screened with thesera from prediabetic relatives obtained as described above (Young, R.A. and R. W. Davis (1984) Science 222:778-782). Isolated recombinantphages were plated on a Luria-Bertani agar plate (150 mm diameter) withEscherichia coli strain (Y1090) at approximately 1×10⁴ plaque-formingunits per plate. After a 3 hour incubation at 42° C., a nitrocellulosefilter (Schleicher & Schuell) saturated with 10 mM isopropylβ-D-thiogalactopyranoside (IPTG; BRL) was overlaid on the agar overnightat 37° C. to induce the expression of β-galactosidase fusion proteins.Following blocking with 1% bovine serum albumin (Sigma) in 1×Tris-Buffer Saline 0.05% Tween (incubation for two hours at roomtemperature), the plates were incubated with 1/500 diluted seraovernight at 4° C. After several washes with 1× Tris Buffer Saline 0.05%Tween, the bound antibodies were detected by incubation with anti-humanIgG alkaline phosphatase 1/100 diluted (two hours at room temperature)(Cappel, Durham, NC).

The phage λgtll library was initially screened with the pool of serafrom three prediabetics. The original positive plaque was replated andrescreened by repeating sequentially until all progeny of plaques wererecognized by the sera. Individual sera were then incubated with amixture of the positive clone and several negative clones, in order toreduce the possibilities of false positivity and to score reactivity ofindividual sera.

From the human islet λgtll expression library, approximately 0.4×10⁶plaques were screened and the PM-1 molecule was identified. This clonewas recognized by 3 out of 6 ICA positive prediabetic subjects sera (ata dilution of 1:500 of the sera) when its fusion protein was induced byisopropyl thiogalactoside (IPTG), whereas the clone did not react with10 control individual sera (FIG. 1). The clone designated PM-1 was 0.95Kb. A labeled cDNA probe derived from the PM-1 clone was used to screenboth a human λgtll islet library and a human insulinoma λgtll library byplaque hybridization, in order to obtain the full length of the molecule(Feinberg, A. P. and B. Vogelstein (1983) Anal. Biochem. 132:6-13). Twoadditional hybridizing and overlapping clones were identified from thehuman islet λgtll expression library after screening approximately3.5×10⁴ plaques. The largest clone contained a 1.78-Kb insert with aninternal EcoRI site. The probe was labeled with (alpha ³² p) dCTP byrandom priming (Wallace, R. B., t al. (1981) Nucleic Acids Res.9:879-894) using Klenow fragment (Amersham Corp.) and used to rescreenthe libraries. DNA sequence analysis (see below) confirmed that theclones contained fragments of the same gene.

EXAMPLE 2 Amplification of λgtll cDNA Insert and Cloning of the PM-1Protein

The λgtll cDNA insert from the positive clone was amplified byPolymerase Chain Reaction (PCR) (Friedman, K. D., at al. (1988) NucleicAcids Res. 16:8718; and Innis, M., e al. In: A Guide to Methods andApplications. Academic Press, New York (1990)), using λgtll primerscomplementary to the β-galactosidase portion of the λgtll template(Primer n. 1218: 5'GGTGGCGACGACTCCTGGAGCCCG 3'; and Primer n. 1222: 5'TTGACACCAGACCAACTGGTAATG 3', New England Biolabs). Reaction mixtures forPCR (0.1 ml) contained cDNA template, 100 pmol each of the primers and2.5 units of Taq DNA Polymerase (Perkin-Elmer/Cetus) in 10 mM Tris.HCl,pH 8.3, 50 mM KCl, 1.5 mM MgCl₂ containing dNTPs at 0.2 mM each and0.01% gelatin. Reactions were carried out in a Perkin-Elmer/Cetusthermal cycler for 30 cycles of denaturation (92° C., 1.5 minutes),annealing (55° C., 1.5 minutes), and elongation (72° C., 1 minute).After EcoRI digestion and fractionation on 1% agarose gel stained withethidium bromide to visualize the products, the PCR product of interestwas excised, purified and subcloned into the EcoRI site of pBluescriptII vector (Stratagene, La Jolla, CA). DNA samples for PCR were obtainedfrom phage suspension.

Nucleotide sequences were determined by using the dideoxynucleotidechain termination method of Sanger et al. (Sanger, F. et al (1977) Proc.Natl. Acad. Sci, USA 74:5463-5467), employing T7 DNA polymerase(Sequenase: United States Biochemical, Cleveland, Ohio). To avoidcompression in G+C-rich sequences, some sequencing reactions wereperformed with dITP alternating with dGTP (Tabor, S. and C. C.Richardson Proc. Natl. Acad. Sci. USA 84:4767-4771).

Following PCR amplification and pBluescript subcloning, partial sequenceindicated that the smallest overlapping clone, whose size is 0.6 kD,reveals a sequence totally contained within the original sequenced PM-1insert (FIG. 2). The results of sequencing both cDNA strands of thelargest clone, whose size is 1.78 Kb, indicates complete identity in theregion of the molecule overlapping with PM-1 and the second clone, andsequence not contained within the previous clone. Analysis of thenucleotide sequence reveals 1785 bases in length with a 1449 base openreading frame coding for 483 amino acids and ending in a poly(A) tail 23bases downstream of the polyadenylation signal (AATAAA). Translation ofthe PM-1 molecule putatively initiates from the first in frame ATGaccording to the criteria defined by Kozak (Kozak, M. (1987) Nucl. AcidRes. 15(20):8125-8132). Upstream from the first ATG, there is an inframe stop codon (TAA) at -72bp. The predicted open reading frame fromthe deduced ATG start codon codes for a protein with an estimated linearM_(r) of 54, 600, which contains one potential N-linked glycosylationsite (FIG. 2).

Sequences were aligned and analyzed using the EUGENE, SAM, PIMA.SH andPROSITE programs. The GenBank (DNA and Amino Acid databank) was searchedfor homologies and the PLSEARCH program was analyzed for proteinsequence patterns derived from the sequences of homologous proteinfamilies (Molecular Biology Computing Research Resource, Dana FarberCancer Institute and Harvard School of Public Health). No significantamino acid or nucleic acid similarities were found, with the exceptionof bovine serum albumin (BSA). Two regions of BSA appear to havesimilarities with the PM-1 protein, suggesting that the PM-1 protein mayshare potential immunogenic epitopes with BSA (FIG. 4). It is known thatantibodies to bovine serum albumin cross-react with an islet protein ofM_(r) 69,000, which can be induced by interferon in RIN tumor cell lines(Martin, J. M., et al. (1991) Ann. Med. 23:447-452; and Dosh, H. M., etal. (1991) Pediatr. Adolesc, Endocrinol. 21). It has been reported thatantibodies raised to one short BSA unique peptide region (amino acidresidues 154-169) on a Western Blot format react with RIN as well asislet proteins with a similar mobility (60-70 kD) than serum from newlydiagnosed IDDM patients. The identity of these islets and RIN tumor BSAcross-reacting protein(s) has not yet been clarified.

A hydrophobicity plot (FIG. 5) generated from the PM-1 deduced aminoacid sequence reveals a number of slightly hydrophobic regions,alternated by several very hydrophilic segments, which suggests that themolecule does not contain any membrane spanning domains, according tothe criteria defined by Kyte and Doolittle (J. Mol. Biol. (1985)157:105-132) and Klein, at al. (Biochem. Biophys. Acta (1985)815:468-476). The segments of hydrophobicity do not appear not to belong enough to be potential transmembrane-spanning regions. The moleculeis extremely hydrophilic with approximately 1/3 of its amino acidresidues charged.

EXAMPLE 3 Production of Anti-PM-1 Antibodies from Synthetic PeptidesDerived from PM-1

Peptides were synthesized from the deduced amino acid sequence of PM-1and used to immunize rabbits to generate antibodies against specificdomains (Van Regenmortel, M. H. V., e al. (1988) In: LaboratoryTechniques in Biochemistry and Molecular Biology (R. H. Burden and P. H.von Knippenberg, eds.) Elsevier, New York and Amsterdam). Two regions ofthe molecule, one corresponding to the C-terminus, residues 471-483:GKTDKEHELLNA, and one to an internal polypeptide near the C-terminusresidues 458-470: ADLDPLSNPDAV were utilized and found to yield antiserawhich immunoprecipitate the native PM-1 molecule. The syntheticpolypeptides were coupled to a carrier protein Keyhole Limpet Hemocyanin(KLH) linked to bromoacetyl bromide. Four female New Zealand whiterabbits were immunized with 1 mg of the KLH-peptide conjugate suspendedin 1 ml of complete Freund's adjuvant. The rabbits were boosted twicewith a further 1 mg of the specific polypeptide in incomplete Freund'sadjuvant at 30 day intervals and serum samples were collected and storedin aliquots at -20° C.

An indirect ELISA assay was performed in order to detect specificantibodies against the PM-1 polypeptides (Harlow, E. and D. Lane (1988),Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, ColdSpring Harbor, N.Y.). 1 μg of specific polypeptide was used to coat eachwell of an Immulon microtiter plate, and after blocking residual bindingof plate with a 1% BSA PBS solution for two hours, appropriate dilutionsof rabbit pre- and post-immune sera were added to each well(1:100-1:32,000) and incubated overnight. All the points were done intriplicate. After washing away unbound antibodies, a solution containingAnti-Rabbit IgG (whole molecule) Peroxidase Conjugate (Sigma) asdeveloping reagent was added to the wells. After two hours incubation,unbound conjugate was washed away and a substrate solution(o-Phenylenediamine Dihydrochloride, OPD, Sigma), was added. The O.D. ofthe solutions in the wells was assessed with a spectrophotometer.

EXAMPLE 4 Northern Analysis of RNA From Various Cell Lines and Tissueswith PM-1 Probes

The cDNA derived from several PM-1 clones was used to probe fortranscripts in human and animal tissues and in several cell lines byNorthern blotting. Total RNAs and poly(A+) RNAs from various tissues andcell lines were prepared by the guanidinium method, enriched for thepolyadenylated (poly-A) fraction with oligo(dT)-cellulose column andanalyzed on Northern blots according to standard procedures (Thomas,P.S. (1980) Proc. Natl. Acad. Sci. USA). The hybridization was carriedout for 18 hours at 42° C. in the prehybridization buffer (50%formamide, 5× SSPE (1× SSPE consists of 150 mM NaCl, 10 mM sodiumphosphate and 1 mM EDTA, pH 7.4, 5× Denhardt's solution, 100 μg/mldenaturated salmon sperm DNA, and 0.1% SDS) (Sambrook, J. et al. (1989)Molecular Cloning: A Laboratory Manual, 12-25-12.28, Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y.) containing alpha ³² p dCTPlabeled cDNA purified probe. The probes used were 0.95 Kb derived fromthe original PM-1 positive clone identified and 1.78 Kb from anoverlapping clone. The nitrocellulose filters were washed in threechanges of 2×-SSC and 0.1% SDS at room temperature each time. The finaltwo washes were carried out in 0.25 SSC and 0.1% SDS from roomtemperature to 65° depending upon the stringency conditions required foreach experiment. Filters were exposed to Kodak film at -70° C. withintensifying screens. Ribosomal bands were used as size markers(Hassoina, N., et al. (1984) Nucl. Acids Res. 12:3563; and Raynal, F.,et al. (1984) FEBS Lett. 167:263).

Both the 0.95 Kb and 1.78 Kb cDNA probes hybridized with an mRNA band of2 Kb from islet derived cells, and in some tissues, with a 5 Kb band.The labeled cDNA PM-1 insert hybridizes with a 2 Kb mRNA in total RNAfrom rat pancreas, brain, cerebellum (in the latter two tissues alsowith a 5 Kb band) (FIG. 6), and lung and kidney (5 Kb band), whereastotal mRNA was undetectable in rat heart, thymus, liver, bowel, lymphnode and salivary gland. A single 2.0 Kb poly(A+) mRNA was detected inhuman thyroid and lung, but not in ovary, placenta and spleen. Theheterogeneity of mRNA size among tissues may be due to an alternativesplicing of the PM-1 gene. Hybridization with a 2 Kb total RNA band wasdetected in human insulinoma, a human islet carcinoid cell line (BON-1),a hamster insulin-producing cell line (HIT), and 3 rodent islet celllines, namely RIN 1046-38, β TC-1 (which is visible after longerexposure), α TC-6. No hybridization was detected in total RNA from threehuman non-islet cell lines, namely HepG2-hepatoma, HeLa-fibroblast,JEG-choriocarcinoma (FIG. 7).

The Northern Analysis of PM-1 transcripts in normal tissues and celllines evaluated suggest that the PM-1 protein may be related to theneuroendocrine system. The detection of mRNA predominantly in neuraltissues, the presence of PM-1 transcripts in islet derived cell linesnamely, RIN, BON-1, HIT, β TC-1, α TC-6 and in insulinoma tissue incontrast to non-neuroendocrine cell lines such as HeLa fibroblasts,JEG-choriocarcinoma and HepG2-hepatoma likely reflects the sharing ofmany molecules between islets and neurons. The low level of PM-1 mRNA inhuman lung and thyroid and the higher level in kidney could be due toPM-1 transcript expression in the small subpopulation of cells ofneuroectodermal origin. Islets and neuronal cells share a large familyof molecules of secretory granules like large dense core granules (e.g.,containing insulin or carboxypeptidase H) as well as synapticmicrovescicular structures (e.g., intracytoplasmic localization ofglutamic acid decarboxylase and synatophysin). Many of the molecules ofboth of these shared structures appear to be prominent targets of theautoimmunity related to Type I diabetes.

EXAMPLE 5 Western Blots of Cells Line Extracts and Tissues with RabbitAntiserum Directed to the PM-1 Molecule

Cell line extracts and total homogenates of rat brain tissues wereprepared as described by Laemmli (Laemmli, V. K. (1970) Nature (London)227:680-685). Cell line extracts and total-homogenate proteins wereseparated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis(SDS-PAGE) and transferred from gel onto nitrocellulose using a constantvoltage of 180 V for four hours. The nitrocellulose was cut into strips,and incubated for two hours at 37° C. in 5% nonfat milk diluted in PBSto block the nonspecific binding sites. The nitrocellulose strips werethen incubated with a 1:100 dilution of a rabbit antiserum directedagainst the C-terminus of the PM-1 molecule and then washed in 5% nonfatmilk diluted in PBS with 0.01% Tween 20. ¹²⁵ I-protein A (Amersham), wasused to detect bound rabbit anti-PM-1 antibodies. A mixture ofindividually colored and purified proteins were used as proteinstandards (RainbowTM Protein Molecular Weight Markers, Amersham):Myosin, MW 200,000, blue; Phosphorylase b, MW 97,400, brown; Bovineserum albumin, MW 69,000, red; Ovalbumin, MW 46,000, yellow; Carbonicanydrase, MW 30,000, orange; Trypsin inhibitor, MW 21,000, green; andLysozyme, MW 14,300, magenta.

Western blots of brain tissue homogenate and cell line extracts (RIN1046-38), revealed a specific band of 69 kD following incubation withthe rabbit antibodies raised to the C terminus of the PM-1 protein andan internal polypeptide. FIG. 8 illustrates that the anti-C terminusPM-1 serum specifically reacted with a protein of 69 kD in RIN and BON-1(visible after longer exposure) cell total homogenate but not with HeLacell line homogenate. In addition, the specific 69 kD band disappearsfollowing absorption with the polypeptide for which specific antibodieswere yielded. The same specific 69 kD reactivity is also detectableusing hyperimmune sera to an internal polypeptide and using rat braintotal homogenate. The deduced amino acid sequence of the PM-1 protein is483 residues with an estimated M_(r) of 54,600. The difference betweenthe western blot size of the protein fractionated in the SDS-PAGE andthe estimated size based upon the deduced amino acid sequence is likelydue to a glycosylation of the molecule (Miletich, J. P., at al. (1990)J. Biol. Chem. 265:11397-11404; and Bause, E. (1983) Biochem, J.204:331-336). Alternatively, the result of the Western blot may be dueto an abnormal migration of the RIN and the brain proteins in SDS-PAGEas a result of solubilzation in detergent-containing buffers aspreviously observed for other proteins (Kumar, K. N., et al. (1991)Nature 354:70-73; and Kumar, K. N., et al. (1991) J. Biol. Chem. (266)23 :14947-14952).

Equivalents

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, numerous equivalents to thespecific procedures described herein. Such equivalents are considered tobe within the scope of this invention and are covered by the followingclaims.

    __________________________________________________________________________    #             SEQUENCE LISTING    - (1) GENERAL INFORMATION:    -    (iii) NUMBER OF SEQUENCES: 2    - (2) INFORMATION FOR SEQ ID NO:1:    -      (i) SEQUENCE CHARACTERISTICS:    #pairs    (A) LENGTH: 1785 base              (B) TYPE: nucleic acid              (C) STRANDEDNESS: single              (D) TOPOLOGY: linear    -     (ii) MOLECULE TYPE: cDNA    -     (ix) FEATURE:              (A) NAME/KEY: CDS              (B) LOCATION: 179..1628    -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:    - CGGGCGGGGG ATACCCCAGG AGATGGGGGT CGAGGAGAGA CCCCGGGGAG TA - #GAGAGAGA      60    - GAAACTCACT CCCCGAGTCC CCGACCCTCC CCAAGCAAGG TTATAATATA AC - #TTATCCTC     120    - TCATGCTTTT TTCCTGCCCC TTCTCCCCAA ATCATCAACA ATAGAAGAAG AA - #GAAAAC     178    - ATG TCA GGA CAC AAA TGC AGT TAT CCC TGG GA - #C TTA CAG GAT CGA TAT     226    Met Ser Gly His Lys Cys Ser Tyr Pro Trp As - #p Leu Gln Asp Arg Tyr    #                 15    - GCT CAA GAT AAG TCA GTT GTA AAT AAG ATG CA - #A CAG AGA TAT TGG GAG     274    Ala Gln Asp Lys Ser Val Val Asn Lys Met Gl - #n Gln Arg Tyr Trp Glu    #             30    - ACG AAG CAG GCC TTT ATT AAA GCC ACA GGG AA - #G AAG GAA GAT GAA CAT     322    Thr Lys Gln Ala Phe Ile Lys Ala Thr Gly Ly - #s Lys Glu Asp Glu His    #         45    - GTT GTT GCC TCT GAC GCG GAC CTG GAT GCC AA - #G CTA GAG CTG TTT CAT     370    Val Val Ala Ser Asp Ala Asp Leu Asp Ala Ly - #s Leu Glu Leu Phe His    #     60    - TCA ATT CAG AGA ACC TGT CTG GAC TTA TCG AA - #A GCA ATT GTA CTC TAT     418    Ser Ile Gln Arg Thr Cys Leu Asp Leu Ser Ly - #s Ala Ile Val Leu Tyr    # 80    - CAA CAG AGG ATA TGT TTC TTG TCT CAA GAA GA - #A AAC GAA CTG GGA AAA     466    Gln Gln Arg Ile Cys Phe Leu Ser Gln Glu Gl - #u Asn Glu Leu Gly Lys    #                 95    - TTT CTT CGA TCC CAA GGT TTC CAA GAT AAA AC - #C AGA GCA GGA AAG ATG     514    Phe Leu Arg Ser Gln Gly Phe Gln Asp Lys Th - #r Arg Ala Gly Lys Met    #           110    - ATG CAA GCG ACA GGA AAG GCC CTC TGC TTT TC - #T TCC CAG CAA AGG TTG     562    Met Gln Ala Thr Gly Lys Ala Leu Cys Phe Se - #r Ser Gln Gln Arg Leu    #       125    - GCC TTA CGA AAT CCT TTG TGT CGA TTT CAC CA - #A GAA GTG GAG ACT TTT     610    Ala Leu Arg Asn Pro Leu Cys Arg Phe His Gl - #n Glu Val Glu Thr Phe    #   140    - CGG CAT CGG GCC ATC TCA GAT ACT TGG CTG AC - #G GTG AAC CGC ATG GAA     658    Arg His Arg Ala Ile Ser Asp Thr Trp Leu Th - #r Val Asn Arg Met Glu    145                 1 - #50                 1 - #55                 1 -    #60    - CAG TGC AGG ACG GAA TAT AGA GGA GCA CTA TT - #A TGG ATG AAG GAC GTG     706    Gln Cys Arg Thr Glu Tyr Arg Gly Ala Leu Le - #u Trp Met Lys Asp Val    #               175    - TCT CAG GAG CTT GAT CCA GAC CTC TAC AAG CA - #A ATG GAG AAG TTC AGG     754    Ser Gln Glu Leu Asp Pro Asp Leu Tyr Lys Gl - #n Met Glu Lys Phe Arg    #           190    - AAG GTG CAA ACA CAA GTG CGC CTT GCA AAA AA - #A AAC TTT GAC AAA TTG     802    Lys Val Gln Thr Gln Val Arg Leu Ala Lys Ly - #s Asn Phe Asp Lys Leu    #       205    - AAG ATG GAT GTG TGT CAA AAA GTG GAT CTT CT - #T GGA GCG AGC AGA TGC     850    Lys Met Asp Val Cys Gln Lys Val Asp Leu Le - #u Gly Ala Ser Arg Cys    #   220    - AAT CTC TTG TCT CAC ATG CTA GCA ACA TAC CA - #G ACC ACT CTG CTT CAT     898    Asn Leu Leu Ser His Met Leu Ala Thr Tyr Gl - #n Thr Thr Leu Leu His    225                 2 - #30                 2 - #35                 2 -    #40    - TTT TGG GAG AAA ACT TCT CAC ACT ATG GCA GC - #C ATC CAT GAG AGT TTC     946    Phe Trp Glu Lys Thr Ser His Thr Met Ala Al - #a Ile His Glu Ser Phe    #               255    - AAA GGT TAT CAA CCA TAT GAA TTT ACT ACT TT - #A AAG AGC TTA CAA GAC     994    Lys Gly Tyr Gln Pro Tyr Glu Phe Thr Thr Le - #u Lys Ser Leu Gln Asp    #           270    - CCT ATG AAA AAA TTA GTT GAG AAA GAA GAG AA - #G AAG AAA ATC AAC CAG    1042    Pro Met Lys Lys Leu Val Glu Lys Glu Glu Ly - #s Lys Lys Ile Asn Gln    #       285    - CAG GAA AGT ACA GAT GCA GCC GTG CAG CAG CC - #G AGC CAA TTA ATT TCA    1090    Gln Glu Ser Thr Asp Ala Ala Val Gln Gln Pr - #o Ser Gln Leu Ile Ser    #   300    - TTA GAG GAA GAA AAC CAG CGC AAG GAA TCC TC - #T AGT TTT AAG ACT GAA    1138    Leu Glu Glu Glu Asn Gln Arg Lys Glu Ser Se - #r Ser Phe Lys Thr Glu    305                 3 - #10                 3 - #15                 3 -    #20    - GAT GGA AAA AGT ATT TTA TCT GCC TTA GAC AA - #A GGC TCT ACA CAT ACT    1186    Asp Gly Lys Ser Ile Leu Ser Ala Leu Asp Ly - #s Gly Ser Thr His Thr    #               335    - GCA TGC TCA GGA CCC ATA GAT GAA CTA TTA GA - #C ATG AAA TCT GAG GAA    1234    Ala Cys Ser Gly Pro Ile Asp Glu Leu Leu As - #p Met Lys Ser Glu Glu    #           350    - GGT GCT TGC CTG GGA CCA GTG GCA GGG ACC CC - #G GAA CCT GAA GGT GCT    1282    Gly Ala Cys Leu Gly Pro Val Ala Gly Thr Pr - #o Glu Pro Glu Gly Ala    #       365    - GAC AAA GAT GAC CTG CTG CTG TTG AGT GAG AT - #C TTC AAT GCT TCC TCC    1330    Asp Lys Asp Asp Leu Leu Leu Leu Ser Glu Il - #e Phe Asn Ala Ser Ser    #   380    - TTG GAA GAG GGC GAG TTC AGC AAA GAG TGG GC - #C GCT GTG TTT GGA GAC    1378    Leu Glu Glu Gly Glu Phe Ser Lys Glu Trp Al - #a Ala Val Phe Gly Asp    385                 3 - #90                 3 - #95                 4 -    #00    - GGC CAA GTG AAG GAG CCA GTG CCC ACT ATG GC - #C CTG GGA GAG CCA GAC    1426    Gly Gln Val Lys Glu Pro Val Pro Thr Met Al - #a Leu Gly Glu Pro Asp    #               415    - CCC AAG GCC CAG ACA GGC TCA GGT TTC CTT CC - #T TCG CAG CTT TTA GAC    1474    Pro Lys Ala Gln Thr Gly Ser Gly Phe Leu Pr - #o Ser Gln Leu Leu Asp    #           430    - CAA AAT ATG AAA GAC TTA CAG GCC TCG CTA CA - #A GAA CCT GCT AAG GCT    1522    Gln Asn Met Lys Asp Leu Gln Ala Ser Leu Gl - #n Glu Pro Ala Lys Ala    #       445    - GCC TCA GAC CTG ACT GCC TGG TTC AGC CTC TT - #C GCT GAC CTC GAC CCA    1570    Ala Ser Asp Leu Thr Ala Trp Phe Ser Leu Ph - #e Ala Asp Leu Asp Pro    #   460    - CTC TCA AAT CCT GAT GCT GTT GGG AAA ACC GA - #T AAA GAA CAC GAA TTG    1618    Leu Ser Asn Pro Asp Ala Val Gly Lys Thr As - #p Lys Glu His Glu Leu    465                 4 - #70                 4 - #75                 4 -    #80    - CTC AAT GCA TGA ATCTGTAC CCTTCGGAGG GCACTCACAT GCCG - #CCCCCA    1668    Leu Asn Ala  *    - GCAGCTCCCC TGGGGGCTAG CAGAAGTATA AAGTGATCAG TATGCTGTTT TA - #ATAATTAT    1728    - GTGCCATTTT AATAAAATGA AAGGGTCAAC GGCCCTGTTA AAAAAAAAAA AA - #AAAAA    1785    - (2) INFORMATION FOR SEQ ID NO:2:    -      (i) SEQUENCE CHARACTERISTICS:    #acids    (A) LENGTH: 483 amino              (B) TYPE: amino acid              (D) TOPOLOGY: linear    -     (ii) MOLECULE TYPE: protein    -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:    - Met Ser Gly His Lys Cys Ser Tyr Pro Trp As - #p Leu Gln Asp Arg Tyr    #                 15    - Ala Gln Asp Lys Ser Val Val Asn Lys Met Gl - #n Gln Arg Tyr Trp Glu    #             30    - Thr Lys Gln Ala Phe Ile Lys Ala Thr Gly Ly - #s Lys Glu Asp Glu His    #         45    - Val Val Ala Ser Asp Ala Asp Leu Asp Ala Ly - #s Leu Glu Leu Phe His    #     60    - Ser Ile Gln Arg Thr Cys Leu Asp Leu Ser Ly - #s Ala Ile Val Leu Tyr    # 80    - Gln Gln Arg Ile Cys Phe Leu Ser Gln Glu Gl - #u Asn Glu Leu Gly Lys    #                 95    - Phe Leu Arg Ser Gln Gly Phe Gln Asp Lys Th - #r Arg Ala Gly Lys Met    #           110    - Met Gln Ala Thr Gly Lys Ala Leu Cys Phe Se - #r Ser Gln Gln Arg Leu    #       125    - Ala Leu Arg Asn Pro Leu Cys Arg Phe His Gl - #n Glu Val Glu Thr Phe    #   140    - Arg His Arg Ala Ile Ser Asp Thr Trp Leu Th - #r Val Asn Arg Met Glu    145                 1 - #50                 1 - #55                 1 -    #60    - Gln Cys Arg Thr Glu Tyr Arg Gly Ala Leu Le - #u Trp Met Lys Asp Val    #               175    - Ser Gln Glu Leu Asp Pro Asp Leu Tyr Lys Gl - #n Met Glu Lys Phe Arg    #           190    - Lys Val Gln Thr Gln Val Arg Leu Ala Lys Ly - #s Asn Phe Asp Lys Leu    #       205    - Lys Met Asp Val Cys Gln Lys Val Asp Leu Le - #u Gly Ala Ser Arg Cys    #   220    - Asn Leu Leu Ser His Met Leu Ala Thr Tyr Gl - #n Thr Thr Leu Leu His    225                 2 - #30                 2 - #35                 2 -    #40    - Phe Trp Glu Lys Thr Ser His Thr Met Ala Al - #a Ile His Glu Ser Phe    #               255    - Lys Gly Tyr Gln Pro Tyr Glu Phe Thr Thr Le - #u Lys Ser Leu Gln Asp    #           270    - Pro Met Lys Lys Leu Val Glu Lys Glu Glu Ly - #s Lys Lys Ile Asn Gln    #       285    - Gln Glu Ser Thr Asp Ala Ala Val Gln Gln Pr - #o Ser Gln Leu Ile Ser    #   300    - Leu Glu Glu Glu Asn Gln Arg Lys Glu Ser Se - #r Ser Phe Lys Thr Glu    305                 3 - #10                 3 - #15                 3 -    #20    - Asp Gly Lys Ser Ile Leu Ser Ala Leu Asp Ly - #s Gly Ser Thr His Thr    #               335    - Ala Cys Ser Gly Pro Ile Asp Glu Leu Leu As - #p Met Lys Ser Glu Glu    #           350    - Gly Ala Cys Leu Gly Pro Val Ala Gly Thr Pr - #o Glu Pro Glu Gly Ala    #       365    - Asp Lys Asp Asp Leu Leu Leu Leu Ser Glu Il - #e Phe Asn Ala Ser Ser    #   380    - Leu Glu Glu Gly Glu Phe Ser Lys Glu Trp Al - #a Ala Val Phe Gly Asp    385                 3 - #90                 3 - #95                 4 -    #00    - Gly Gln Val Lys Glu Pro Val Pro Thr Met Al - #a Leu Gly Glu Pro Asp    #               415    - Pro Lys Ala Gln Thr Gly Ser Gly Phe Leu Pr - #o Ser Gln Leu Leu Asp    #           430    - Gln Asn Met Lys Asp Leu Gln Ala Ser Leu Gl - #n Glu Pro Ala Lys Ala    #       445    - Ala Ser Asp Leu Thr Ala Trp Phe Ser Leu Ph - #e Ala Asp Leu Asp Pro    #   460    - Leu Ser Asn Pro Asp Ala Val Gly Lys Thr As - #p Lys Glu His Glu Leu    465                 4 - #70                 4 - #75                 4 -    #80    - Leu Asn Ala    __________________________________________________________________________

We claim:
 1. A method of detecting antibodies against PM-1 protein in abiological fluid to identify an individual at risk of developingdiabetes, comprising:a. contacting PM-1 protein comprising an amino acidsequence shown in the Sequence Listing with a biological fluid of theindividual under conditions which allow formation of complexes betweenthe PM-1 protein and antibodies against the PM-1 protein in thebiological fluid; andb. detecting the formation of complexes as anindication of the presence of antibody against PM-1 protein in thebiological fluid and identifying the individual at risk of developingdiabetes.
 2. The method of claim 1, wherein the biological fluid ishuman serum or plasma.
 3. The method of claim 1, wherein the PM-1protein is produced by recombinant DNA techniques.
 4. A method ofdetecting antibody against PM-1 protein in a biological fluid toidentify an individual at risk of developing diabetes, comprising:a.providing a solid phase support to which is attached PM-1 proteincomprising an amino acid sequence shown in the Sequence Listingimmunoreactive with antibody against PM-1 protein; b. incubating thesolid phase support with a sample of the biological fluid to be testedunder conditions which allow antibody in the sample to bind to PM-1protein attached to the solid phase support; c. separating the solidphase support from the sample; d. determining the antibody bound to thesolid phase support as an indication of the presence of antibody againstPM-1 protein in the biological fluid and identifying the individual asat risk of developing diabetes.
 5. The method of claim 4, wherein thePM-1 protein attached to the solid phase support is produced byrecombinant DNA techniques.
 6. The method of claim 4, wherein thebiological fluid is human serum or plasma.
 7. The method of claim 4,wherein the step of determining the antibody bound to the solid phasesupport comprises:a. incubating the solid phase support with a labeledantibody against immunoglobulin of the species from which the biologicalfluid is derived; b. separating the solid phase support from the labeledantibody; c. detecting the label associated with the solid phase supportas an indication of antibody against PM-1 protein in the biologicalfluid.
 8. The method of claim 7, wherein the labeled antibody is labeledantihuman IgG antibody.
 9. A kit for detecting antibody against PM-1protein in a biological fluid comprising, in separate containers:a. asolid phase support to which is attached PM-1 protein comprising anamino acid sequence shown in the Sequence Listing immunoreactive withantibody against PM-1 protein; and b. a labeled anti-(human IgG)antibody.
 10. The kit of claim 9, wherein the PM-1 protein attached tothe solid phase support is produced by recombinant DNA techniques. 11.The kit of claim 9 further comprising:c. a positive control in the formof a fluid sample which contains antibody against PM-1 protein; and d. anegative control in the form of a fluid sample which does not containantibody against PM-1 protein.